Anne Samuel

Stock Analyst at JP Morgan

(1.34)
# 1610
Out of 5,240 analysts
73
Total ratings
41.67%
Success rate
18.09%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
Veeva Systems
Maintains: Neutral
208 218
210.79 3.42% 5 Dec 16, 2024
Progyny
Downgrades: Neutral
22 17
20.08 -15.34% 6 Dec 2, 2024
Evolent Health
Maintains: Overweight
45 15
11.26 33.21% 10 Nov 22, 2024
Doximity
Maintains: Neutral
30 48
50.67 -5.27% 5 Nov 21, 2024
Omnicell
Maintains: Neutral
37 44
42.3 4.02% 4 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
279 240
198.04 21.19% 5 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
27 28
26.1 7.28% 2 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
21 19
21.47 -11.5% 4 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
19 21
23.97 -12.39% 3 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
10 13
5.88 121.09% 3 Sep 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
24 27
37.36 -27.73% 2 Aug 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
7 5
3.92 27.55% 1 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
86 108
103.56 4.29% 7 Apr 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
20 11
n/a n/a 3 Dec 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
30 25
n/a n/a 1 Dec 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
19 20
n/a n/a 1 Nov 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
32 31
n/a n/a 2 Sep 6, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
12
n/a n/a 1 Jul 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
14 15
n/a n/a 4 Apr 24, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
148 159
n/a n/a 4 Apr 24, 2018